1. Home
  2. EOLS vs AUTL Comparison

EOLS vs AUTL Comparison

Compare EOLS & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$7.61

Market Cap

500.0M

Sector

Health Care

ML Signal

HOLD

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

HOLD

Current Price

$1.62

Market Cap

596.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EOLS
AUTL
Founded
2012
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
500.0M
596.2M
IPO Year
2018
2025

Fundamental Metrics

Financial Performance
Metric
EOLS
AUTL
Price
$7.61
$1.62
Analyst Decision
Buy
Strong Buy
Analyst Count
6
9
Target Price
★ $15.00
$8.75
AVG Volume (30 Days)
669.0K
★ 1.7M
Earning Date
11-04-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 1.23
N/A
EPS
★ N/A
N/A
Revenue
★ $297,176,000.00
$10,120,000.00
Revenue This Year
$12.44
$98.68
Revenue Next Year
$17.37
$28.47
P/E Ratio
★ N/A
N/A
Revenue Growth
11.61
★ 496.00
52 Week Low
$3.86
$1.18
52 Week High
$9.31
$2.58

Technical Indicators

Market Signals
Indicator
EOLS
AUTL
Relative Strength Index (RSI) 51.57 40.67
Support Level $7.59 $1.38
Resistance Level $7.83 $1.73
Average True Range (ATR) 0.32 0.09
MACD 0.02 -0.00
Stochastic Oscillator 79.57 32.81

Price Performance

Historical Comparison
EOLS
AUTL

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: